Research paper efficacy and safety of telitacicept combined with standard therapy for lupus nephritis: a single-center real-world study
Telitacicept combined with standard therapy demonstrated significant efficacy in LN with an acceptable safety profile, achieving high response rates, reduced proteinuria, improved immunological parameters, and substantial glucocorticoid-sparing effects.
Authors
- Youyang Fan
- Aibing Zhang (ORCID: https://orcid.org/0000-0003-3919-7843)
- Jiashun Zeng (ORCID: https://orcid.org/0000-0003-0870-4822)
- Lei Yang (ORCID: https://orcid.org/0000-0002-0785-2084)
- Pengjia Wu
- Na Li (ORCID: https://orcid.org/0000-0002-8961-5620)
- Rui Li (ORCID: https://orcid.org/0000-0001-7857-9735)
- Xiaoxia Liu (ORCID: https://orcid.org/0000-0001-8188-4562)
- Ting Tian (ORCID: https://orcid.org/0009-0009-6094-4904)
- Longyan Qin
Institutions
- Guiyang Medical University (CN)
- Affiliated Hospital of Guizhou Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-09-02
- DOI
- https://doi.org/10.3389/fimmu.2025.1645826
- Primary Topic
- Systemic Lupus Erythematosus Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Guizhou Medical University